NO20005981L - Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- <kappa>B - Google Patents

Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- <kappa>B

Info

Publication number
NO20005981L
NO20005981L NO20005981A NO20005981A NO20005981L NO 20005981 L NO20005981 L NO 20005981L NO 20005981 A NO20005981 A NO 20005981A NO 20005981 A NO20005981 A NO 20005981A NO 20005981 L NO20005981 L NO 20005981L
Authority
NO
Norway
Prior art keywords
activation
acid derivatives
hydroxy
transcription factor
kappa
Prior art date
Application number
NO20005981A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005981D0 (no
Inventor
Manuel Merlos Roca
Alberto Fernandez De Arriba
Fernando Cavalcanti De Maria
Augusti Miralles Acosta
Mariano Sanchez Crespo
Julian Garcia Rafanell
Javier Forn Dalmau
Original Assignee
Uriach & Cia Sa J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uriach & Cia Sa J filed Critical Uriach & Cia Sa J
Publication of NO20005981D0 publication Critical patent/NO20005981D0/no
Publication of NO20005981L publication Critical patent/NO20005981L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20005981A 1998-05-27 2000-11-27 Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- <kappa>B NO20005981L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009801154A ES2136581B1 (es) 1998-05-27 1998-05-27 Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
PCT/ES1999/000154 WO1999061030A1 (es) 1998-05-27 1999-05-26 USO DE DERIVADOS DEL ACIDO 2-HIDROXI-4-TRIFLUOROMETILBENZOICO COMO INHIBIDORES DE LA ACTIVACION DEL FACTOR DE TRANSCRIPCION NUCLEAR NF-λB

Publications (2)

Publication Number Publication Date
NO20005981D0 NO20005981D0 (no) 2000-11-27
NO20005981L true NO20005981L (no) 2000-12-12

Family

ID=8304002

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005981A NO20005981L (no) 1998-05-27 2000-11-27 Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- <kappa>B

Country Status (14)

Country Link
US (2) US6414025B1 (de)
EP (2) EP1362592A1 (de)
JP (1) JP2002516283A (de)
KR (2) KR100762156B1 (de)
AT (1) ATE245987T1 (de)
AU (1) AU3828699A (de)
BR (1) BR9911598A (de)
CA (1) CA2332863A1 (de)
DE (1) DE69910019T2 (de)
DK (1) DK1082962T3 (de)
ES (2) ES2136581B1 (de)
NO (1) NO20005981L (de)
PT (1) PT1082962E (de)
WO (1) WO1999061030A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2154242B1 (es) * 1999-09-03 2001-10-16 Uriach & Cia Sa J Nuevos sistemas polimericos biocompatibles portadores de triflusal o htb.
US20040101488A1 (en) * 2000-03-24 2004-05-27 Balaram Ghosh Method for the prevention of septic shock lethality using curcumin
ES2190373B1 (es) * 2001-12-07 2004-10-16 J. URIACH &amp; CIA, S.A. Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.
JP2006502183A (ja) 2002-09-20 2006-01-19 アルコン,インコーポレイテッド ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用
DK2444092T3 (en) 2008-05-28 2015-09-28 Reveragen Biopharma Inc Non-hormonal steroidmodulatorer of NF-? B for the treatment of disease
NZ617779A (en) 2009-03-18 2015-08-28 Resverlogix Corp Novel anti-inflammatory agents
EP2556083A4 (de) 2010-04-05 2013-12-04 Validus Biopharma Inc Nichthormonale steroide modulatoren von nf-kappa-b zur krankheitsbehandlung
CN103665012B (zh) * 2013-12-06 2016-06-22 辽宁师范大学 新型三氟柳无机药物化合物及合成方法
WO2017004205A1 (en) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
US20180016314A1 (en) * 2016-07-12 2018-01-18 Children's Hospital Medical Center Treatment of disease via transcription factor modulation
EP3525780B1 (de) * 2016-10-14 2021-06-02 Institut Pasteur De Montevideo Pluripotent entzündungshemmende und metabolische modulatoren zur behandlung von entzündungsbedingten zuständen
KR101975603B1 (ko) 2018-09-14 2019-08-28 이영문 조력 발전장치
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096252A (en) * 1976-06-10 1978-06-20 J. Uriach & Cia S.A. 4-Trifluoromethylbenzoic acid derivatives as thromboembolic agents
IT1276071B1 (it) * 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria

Also Published As

Publication number Publication date
ES2136581B1 (es) 2000-09-16
KR20010052404A (ko) 2001-06-25
US6610745B2 (en) 2003-08-26
KR100762156B1 (ko) 2007-10-04
DK1082962T3 (da) 2003-11-24
EP1082962A1 (de) 2001-03-14
CA2332863A1 (en) 1999-12-02
DE69910019T2 (de) 2004-05-06
US6414025B1 (en) 2002-07-02
EP1082962B1 (de) 2003-07-30
ES2136581A1 (es) 1999-11-16
PT1082962E (pt) 2003-11-28
WO1999061030A1 (es) 1999-12-02
KR100713601B1 (ko) 2007-05-02
EP1362592A1 (de) 2003-11-19
US20030032630A1 (en) 2003-02-13
KR20070006943A (ko) 2007-01-11
BR9911598A (pt) 2001-02-13
JP2002516283A (ja) 2002-06-04
ATE245987T1 (de) 2003-08-15
NO20005981D0 (no) 2000-11-27
AU3828699A (en) 1999-12-13
DE69910019D1 (de) 2003-09-04
ES2204129T3 (es) 2004-04-16

Similar Documents

Publication Publication Date Title
TR200201317T2 (tr) Sinerjistik kombinasyon.
TR200200205T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
NO983019L (no) Fremgangsmåte for inhibering av fotoaldring av hud
TR199801315T2 (xx) X sendromunun tedavisi i�in bir ppar-alpha ve ppar-gamma antagonistinin kullan�lmas�.
BG100960A (bg) Дозирани форми с контролирано освобождаване на азитромицин
ES2114487B1 (es) Mezcla estabilizante sinergistica.
BR9806752A (pt) Ftalazinonas.
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
DK0840606T3 (da) Små di- og trivalente molekyler som selectininhibitorer
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
DK0942751T3 (da) Præparater til behandling af perifere nuropatier indeholdende antidepressiver og/eller monoaminoxidase-inhibitorer og/eller vitamin B12 og/eller prekursere til eller inducere af en neurotransmitter
NO985964L (no) Administrasjonskur for H+, K+ -ATPase-inhibitorer
NO20005981D0 (no) Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- &lt;kappa&gt;B
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
TR199900951T2 (xx) G���s kanserinin engellenmesi i�in y�ntemler.
WO2002005642A3 (en) Synergistic biocidal compositions
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
NO20001758L (no) FremgangsmÕter og blandinger for behandling av leddgikt
NO20003813L (no) FremgangsmÕter for Õ redusere eller forhindre smerte ved bruk av spicamycin eller derivater derav
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
NO20012777L (no) Anvendelse av riluzol ved behandling av akustiske traumer
ES2135535T3 (es) Derivados tiazolotriazol y tiazolodiazol con actividad fungicida.
PL372924A1 (en) Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application